Rachel W. Humphrey, MD

Rachel W. Humphrey, MD is a highly accomplished medical professional with extensive experience in the biotech and pharmaceutical industry, particularly in oncology and immunotherapy drug development. Here are some key details about her:

Current Positions

Rachel W. Humphrey currently serves as:

• President and Founding CEO of Normunity since October 202113
• Independent Board Director at Pyxis Oncology since August 202213
• Independent Board Director at Sporos Bioventures since October 202113
• Scientific Advisory Board Member at Grey Wolf Therapeutics and HotSpot Therapeutics since December and October 2021, respectively3

Professional Experience

Dr. Humphrey has over 25 years of experience in clinical drug development, with a focus on cancer treatments and immunotherapies.2 Her career highlights include:

• Leading the development of blockbuster cancer therapies such as:

  • Yervoy® (ipilimumab) at Bristol-Myers Squibb
  • Imfinzi® (durvalumab) at AstraZeneca
  • Nexavar® (sorafenib) at Bayer2

• Holding leadership positions at various biotech companies:

  • Chief Medical Officer at Black Diamond Therapeutics (2020-2021)
  • SVP and Chief Medical Officer at CytomX Therapeutics (2015-2019)
  • Vice President and Head of Immuno-Oncology at Eli Lilly and Company (2015)
  • SVP and Head of Immuno-Oncology at AstraZeneca (2013-2014)3

Education

• BA in Biochemistry from Harvard University (1979-1983)
• MD from Case Western Reserve University School of Medicine (1985-1989)
• Residency in Internal Medicine at The Johns Hopkins University School of Medicine (1989-1992)12

Expertise

Dr. Humphrey is known for her expertise in:

• Clinical drug development
• Oncology research
• Immunotherapies
• Leadership in biotech and pharmaceutical companies

Her extensive experience and track record in developing successful cancer therapies make her a valuable asset to the boards and companies she serves.